Cargando…
Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment
Lung cancer is one of the most common cancers in the world with a high mortality rate. Zein is a protein compound whose protein isolate is not useful and whose protein hydrolysis produces biological activity. By encapsulating this bioactive compound inside the nanoparticles (NPs), it causes itself t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979517/ https://www.ncbi.nlm.nih.gov/pubmed/35363101 http://dx.doi.org/10.1080/10717544.2022.2057618 |
_version_ | 1784681192948236288 |
---|---|
author | Mazloum-Ravasan, Sahand Mohammadi, Maryam Hiagh, Elaheh Madadi Ebrahimi, Alireza Hong, Joo-Hyun Hamishehkar, Hamed Kim, Ki Hyun |
author_facet | Mazloum-Ravasan, Sahand Mohammadi, Maryam Hiagh, Elaheh Madadi Ebrahimi, Alireza Hong, Joo-Hyun Hamishehkar, Hamed Kim, Ki Hyun |
author_sort | Mazloum-Ravasan, Sahand |
collection | PubMed |
description | Lung cancer is one of the most common cancers in the world with a high mortality rate. Zein is a protein compound whose protein isolate is not useful and whose protein hydrolysis produces biological activity. By encapsulating this bioactive compound inside the nanoparticles (NPs), it causes itself to reach the tumor site and destroy it rapidly. In this study, the effects of zein hydrolysate (ZH) and nano-liposomal ZH (N-ZH) were investigated on the human A549 cell line. Western blotting and cell cycle analyses showed that ZH and N-ZH caused cytotoxicity. They induced apoptosis via cell cycle arrest at the G0 phase, as well as significant increases in pro-apoptotic genes, such as Bax, caspase-3, -8, -9, and p53, accompanied with significant decreases in the anti-apoptotic marker Bcl-2. Based on the results, the cytotoxic and anticancer effects of N-ZH were higher than those of free ZH. In conclusion, liposomes improved the performance of ZH and dramatically reduced the IC(50) value of ZH. These findings provided the experimental evidence that N-ZH with favorable anticancer activity can be used as a therapeutic agent and strategy for lung cancer treatment in future clinical trials. |
format | Online Article Text |
id | pubmed-8979517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-89795172022-04-05 Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment Mazloum-Ravasan, Sahand Mohammadi, Maryam Hiagh, Elaheh Madadi Ebrahimi, Alireza Hong, Joo-Hyun Hamishehkar, Hamed Kim, Ki Hyun Drug Deliv Research Article Lung cancer is one of the most common cancers in the world with a high mortality rate. Zein is a protein compound whose protein isolate is not useful and whose protein hydrolysis produces biological activity. By encapsulating this bioactive compound inside the nanoparticles (NPs), it causes itself to reach the tumor site and destroy it rapidly. In this study, the effects of zein hydrolysate (ZH) and nano-liposomal ZH (N-ZH) were investigated on the human A549 cell line. Western blotting and cell cycle analyses showed that ZH and N-ZH caused cytotoxicity. They induced apoptosis via cell cycle arrest at the G0 phase, as well as significant increases in pro-apoptotic genes, such as Bax, caspase-3, -8, -9, and p53, accompanied with significant decreases in the anti-apoptotic marker Bcl-2. Based on the results, the cytotoxic and anticancer effects of N-ZH were higher than those of free ZH. In conclusion, liposomes improved the performance of ZH and dramatically reduced the IC(50) value of ZH. These findings provided the experimental evidence that N-ZH with favorable anticancer activity can be used as a therapeutic agent and strategy for lung cancer treatment in future clinical trials. Taylor & Francis 2022-04-01 /pmc/articles/PMC8979517/ /pubmed/35363101 http://dx.doi.org/10.1080/10717544.2022.2057618 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Mazloum-Ravasan, Sahand Mohammadi, Maryam Hiagh, Elaheh Madadi Ebrahimi, Alireza Hong, Joo-Hyun Hamishehkar, Hamed Kim, Ki Hyun Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment |
title | Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment |
title_full | Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment |
title_fullStr | Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment |
title_full_unstemmed | Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment |
title_short | Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment |
title_sort | nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979517/ https://www.ncbi.nlm.nih.gov/pubmed/35363101 http://dx.doi.org/10.1080/10717544.2022.2057618 |
work_keys_str_mv | AT mazloumravasansahand nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment AT mohammadimaryam nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment AT hiaghelahehmadadi nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment AT ebrahimialireza nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment AT hongjoohyun nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment AT hamishehkarhamed nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment AT kimkihyun nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment |